Royalty Pharma plc
RPRXNASDAQHealthcareMedical - Pharmaceuticals
Previous close
$61.31
+$0.73 · +1.21%
RPRX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Buy
Favorable setup — positive multi-factor alignment
Valuation
59
Fair Value
Momentum
63
Gaining
Sentiment
63
Bullish
Risk resilience
82
Low Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Pablo Legorreta
- Listed since
- Jun 16, 2020
- Employees
- 100
Market position
Day range
Current $61.31
52-week range
Current $61.31
- Open
- $60.53
- Previous close
- $60.58
- Volume
- 1.94M
- 0.56× average
- Average volume
- 3.44M
- Average daily volume
- Market cap
- 27.18B USD
- Beta
- 0.43
- Market reference 1
- 50-day average
- $57.3539
- +6.90% above average
- 200-day average
- $48.0844
- +27.50% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 25.02B USD
- P/E (TTM)
- 25.44×
- P/B (TTM)
- 3.99×
- P/S (TTM)
- 10.72×
- EV / EBITDA
- 15.3×
- Earnings yield
- 4.62%
- Free cash flow yield
- 14.92%
- Dividend yield
- 1.51%
Profitability & efficiency
- Gross margin
- 89.38%
- Operating margin
- 62.34%
- Net margin
- 32.15%
- Return on equity
- 11.90%
- Return on assets
- 3.93%
- Return on invested capital
- 8.95%
Financial health
- Debt / equity
- 1.31×
- Current ratio
- 0.97×
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$59.50
2.95% downsideRPRX peers
ETFs holding RPRX
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Extended Market ETFVXF262.52M0.27%93.7B USD0.05%$245.53+0.82%
VictoryShares Free Cash Flow ETFVFLO171.11M1.59%10.72B USD0.44%$55.45+0.69%
iShares Russell Mid-Cap ETFIWR102.03M0.18%57.66B USD0.18%$113.44+0.70%
Vanguard High Dividend Yield ETFVYM97.3M0.10%99.2B USD0.04%$164.97+0.59%
iShares U.S. Pharmaceuticals ETFIHE75.62M4.39%1.74B USD0.37%$106.79+1.01%
Capital Group Dividend Growers ETFCGDG67.77M1.20%5.17B USD0.47%$38.91+0.65%
Schwab U.S. Mid-Cap ETFSCHM65.81M0.44%15.12B USD0.03%$36.16+0.67%
iShares Russell 1000 Value ETFIWD55.56M0.07%83.81B USD0.18%$257.29+0.44%Vanguard Extended Market ETFVXF- Market value
- 262.52M
- Weight
- 0.27%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
VictoryShares Free Cash Flow ETFVFLO- Market value
- 171.11M
- Weight
- 1.59%
- AUM
- 10.72B USD
- Expense ratio
- 0.44%
- Price / 1D
- $55.45+0.69%
iShares Russell Mid-Cap ETFIWR- Market value
- 102.03M
- Weight
- 0.18%
- AUM
- 57.66B USD
- Expense ratio
- 0.18%
- Price / 1D
- $113.44+0.70%
Vanguard High Dividend Yield ETFVYM- Market value
- 97.3M
- Weight
- 0.10%
- AUM
- 99.2B USD
- Expense ratio
- 0.04%
- Price / 1D
- $164.97+0.59%
iShares U.S. Pharmaceuticals ETFIHE- Market value
- 75.62M
- Weight
- 4.39%
- AUM
- 1.74B USD
- Expense ratio
- 0.37%
- Price / 1D
- $106.79+1.01%
Capital Group Dividend Growers ETFCGDG- Market value
- 67.77M
- Weight
- 1.20%
- AUM
- 5.17B USD
- Expense ratio
- 0.47%
- Price / 1D
- $38.91+0.65%
Schwab U.S. Mid-Cap ETFSCHM- Market value
- 65.81M
- Weight
- 0.44%
- AUM
- 15.12B USD
- Expense ratio
- 0.03%
- Price / 1D
- $36.16+0.67%
iShares Russell 1000 Value ETFIWD- Market value
- 55.56M
- Weight
- 0.07%
- AUM
- 83.81B USD
- Expense ratio
- 0.18%
- Price / 1D
- $257.29+0.44%
Continue in GoAI
Research RPRXresearch.disclaimer